natgillin/translations-raw huggingface dataset:
The combination of trazodone with indinavir/ritonavir should be used with caution, initiating trazodone at the lowest dose and monitoring for clinical response and tolerability. 
Kombinacijo trazodona in indinavirja/ritonavirja je treba uporabljati previdno, pri čemer je treba terapijo s trazodonom začeti z najmanjšim odmerkom ter spremljati klinični odziv in toleranco.
The suggestion is based on limited published data (see section 5.2). 
To temelji na omejenih objavljenih podatkih (glejte poglavje 5.2).
The recommended dose of CRIXIVAN is: 
Priporočeni odmerek zdravila CRIXIVAN je:
The design of the study does not allow for definitive evaluation of the effect of saquinavir on indinavir, but suggests there is less than a two-fold increase in indinavir AUC8h during co-administration with saquinavir 
Oblika študije ne omogoča natančne ocene učinka sakvinavirja na indinavir, vendar pa kaže, da se med sočasnim dajanjem s sakvinavirjem pojavi manj kot dvakratno povečanje AUC8h indinavirja.
• If this happens, your treatment will stop working. 
• V tem primeru bo zdravljenje s tem zdravilom postalo neučinkovito.
For information regarding diet or the effect of food on indinavir absorption (see sections 4.2 and 5.2). 
(Za informacije glede diete ali vpliva hrane na absorpcijo indinavirja glejte poglavji 4.2 in 5.2).
When loss of viral RNA suppression occurred, it was typically associated with replacement of circulating susceptible virus with resistant viral variants. 
Kadar je prišlo do izgube supresije virusne RNA, je bilo to ponavadi povezano z zamenjavo cirkulirajočega občutljivega virusa z rezistentno virusno različico.
In case of concomitant antiviral therapy for hepatitis B or C, please refer also to the relevant product information for these medicinal products. 
V primeru sočasnega zdravljenja hepatitisa B ali C z drugimi protivirusnimi zdravili, prosimo, preberite ustrezno navodilo za uporabo teh zdravil.
PDE5 INHIBITOR Sildenafil, tadalafil 
ZAVIRALEC PDE5 Sildenafil, tadalafil
Given that substantially lower antepartum exposures have been observed in a small study of HIV-infected pregnant patients and the limited data in this patient population, indinavir use is not recommended in HIV-infected pregnant patients (see section 5.2). 
Glede na to, da so v majhni raziskavi nosečih žensk, okuženih s HIV, opazovali znatno manjšo predporodno izpostavljenost, in glede na omejene podatke pri tej populaciji bolnic, uporabe indinavira pri nosečih ženskah, okuženih s HIV, ne priporočamo (glejte poglavje 5.2).
Therefore, therapy with indinavir should be initiated at the recommended dose to increase suppression of viral replication and therefore inhibit the emergence of resistant virus. 
Zato je zdravljenje z indinavirjem treba začeti s priporočenim odmerkom, da bi se povečala supresija virusnega podvajanja in tako preprečil pojav rezistentnega virusa.
Because it is unknown whether indinavir will exacerbate physiologic hyperbilirubinaemia in neonates, careful consideration must be given to the use of indinavir in pregnant women at the time of delivery (see section 4.8). 
Ker ni znano, če indinavir poslabša fiziološko hiperbilirubinemijo pri novorojenčkih, je treba skrbno pretehtati uporabo indinavirja pri nosečnicah v času poroda (glejte poglavje 4.8).
• If you are also taking ritonavir, then you can take CRIXIVAN at any time of the day with or without food. 
• Če jemljete tudi ritonavir, lahko vzamete zdravilo CRIXIVAN kadar koli v dnevu z ali brez hrane.
See your doctor straight away if you notice any of the following serious side effects - you may need urgent medical treatment: 
Če opazite katerega koli od naslednjih resnih neželenih učinkov, se nemudoma posvetujte z zdravnikom - morda boste potrebovali nujno zdravljenje:
ANTICOAGULANT Warfarin 
ANTIKOAGULANT Varfarin
How CRIXIVAN works CRIXIVAN treats HIV and helps to lower the number of HIV particles in your blood. 
Kako zdravilo CRIXIVAN deluje Zdravilo CRIXIVAN zdravi okužbo s HIV in pomaga zmanjšati število HIV delcev v vaši krvi.
Pharmacotherapeutic group: Antivirals for systemic use, protease inhibitor, ATC code JO5AE02 
Farmakoterapevtska skupina: Zdravila za sistemsko zdravljenje virusnih infekcij, zaviralec proteaze, Oznaka ATC: JO5AE02
Such problems might be due to a bone disease called ‘osteonecrosis' (loss of blood supply to the bone causing bone death), which can occur months to years after starting HIV therapy. 
Take težave lahko povzročijo bolezen kosti, imenovana 'osteonekroza' (odmiranje kosti zaradi nezadostne prekrvavitve kosti), ki se lahko pojavi več mesecev ali let po začetku zdravljenja okužbe z virusom HIV.
• Take this medicine by mouth. 
• Vzemite skozi usta.
Mean urinary excretion of unchanged medicinal product following single dose administration in the fasted state was 10.4 % following a 700-mg dose, and 12.0 % following a 1,000-mg dose. 
Povprečen delež izločanja nespremenjenega zdravila v urinu po enkratnem odmerku na tešče je znašal 10,4 % po 700 mg in 12,0 % po 1000 mg odmerku.
Six of these 11 (55 %) patients had mean indinavir plasma concentrations 8 hours postdose (Cmin) below assay threshold of reliable quantification. 
Šest preiskovank med temi 11 (55 %) je imelo povprečno plazemsko koncentracijo indinavirja 8 ur po odmerku (cmin) nižjo od praga zanesljive kvantitativne določitve pri testu.
Loss of suppression of viral RNA levels occurred in some patients; however, CD4 cell counts were often sustained above pre-treatment levels. 
Pri nekaterih bolnikih je prišlo do izgube supresije ravni virusne RNA, vendar pa je število CD4 celic pogosto ostalo višje, kot je bilo pred zdravljenjem.
• sildenafil, vardenafil, tadalafil - used for impotence 
• sildenafil, vardenafil, tadalafil - za impotenco
Caution is warranted and clinical monitoring of patients is recommended. 
Priporočata se previdnost in klinično spremljanje bolnikov.
The following effects may happen: 
Pojavijo se lahko naslednji simptomi:
The recommendation is based on limited pharmacokinetic data (see section 5.2). 
Priporočilo temelji na omejenih farmakokinetičnih podatkih (glejte poglavje 5.2).
Renal clearance (116 mL/min) of indinavir is concentration-independent over the clinical dose range. 
Ledvični očistek indinavirja (116 ml/min) je v kliničnem odmernem območju neodvisen od koncentracije.
CRIXIVAN is indicated in combination with antiretroviral nucleoside analogues for the treatment of HIV-1 infected adults. 
Zdravilo CRIXIVAN je v kombinaciji s protiretrovirusnimi nukleozidnimi analogi indicirano za zdravljenje z virusom HIV-1 okuženih odraslih.
Caution is advised. 
Potrebna je previdnost.
Resistance was correlated with the accumulation of mutations in the viral genome that resulted in the expression of amino acid substitutions in the viral protease. 
Rezistenca je bila povezana s kopičenjem mutacij v virusnem genomu, kar je povzročilo ekspresijo aminokislinskih substitucij v virusni proteazi.
Also some other medicines can affect the way CRIXIVAN works. 
Prav tako druga zdravila lahko vplivajo na delovanje zdravila CRIXIVAN.
It is recommended that HIV infected women do not breast feed their infants under any circumstances in order to avoid transmission of HIV. 
Priporočeno je, naj ženske okužene z virusom HIV nikakor ne dojijo, da bi se izognile prenosu virusa HIV na novorojenčka.
Crixivan, 800 mg every 8 hours + zidovudine 200 mg every 8 hours and lamivudine 150 mg twice a day). 
CRIXIVAN, 800 mg vsakih 8 ur + zidovudin 200 mg vsakih 8 ur in lamivudin 150 mg dvakrat na dan).
• warfarin - used to thin the blood 
• varfarin - za redčenje krvi
• atorvastatin, rosuvastatin, pravastatin, fluvastatin - used to lower cholesterol 
• atorvastatin, rosuvastatin, pravastatin, fluvastatin - za zniževanje holesterola
Thirty subjects completed 48 weeks of treatment. 
48-tedensko zdravljenje je zaključilo trideset preizkušancev.
• autoimmune disorders (a condition that occurs when the immune system attacks healthy body tissue) may also occur after you start taking medicines for the treatment of your HIV infection. 
• avtoimune bolezni (stanje, ko imunski sistem napade zdravo telesno tkivo) se lahko pojavijo po začetku jemanja zdravil za zdravljenje okužbe z virusom HIV.
In addition, talk to your doctor, pharmacist or nurse before taking CRIXIVAN if you are taking any of the following medicines since your doctor may want to adjust the dose of your medicines: 
Poleg tega se posvetujte z zdravnikom, farmacevtom ali medicinsko sestro, preden vzamete zdravilo CRIXIVAN, če jemljete katero od naslednjih zdravil, saj vam bo zdravnik morda prilagodil odmerek zdravil:
If you notice any symptoms of infection, please inform your doctor immediately. 
Če opazite kakršne koli znake okužbe, takoj obvestite zdravnika.
However, patients should be informed that dizziness and blurred vision have been reported during treatment with indinavir. 
Bolnike pa je treba opozoriti na to, da so med zdravljenjem z indinavirjem poročali o omotici in zamegljenem vidu.
• kidney problems (including inflammation of the kidneys, kidney stones, or back pain with or without blood in your urine) 
• težave z ledvicami (vključno z vnetjem ledvic, ledvičnimi kamni ali bolečinami v hrbtu z ali brez krvi v urinu)
In patients at increased risk, urinary screening should be considered. 
Pri bolj ogroženih bolnikih so potrebne preiskave urina.
In vitro studies with human liver microsomes indicated that CYP3A4 is the only P450 isozyme that plays a major role in the oxidative metabolism of indinavir. 
In vitro raziskave s človeškimi jetrnimi mikrosomi so pokazale, da je CYP3A4 edini P450 izoencim, ki igra pomembno vlogo v oksidativnem metabolizmu indinavirja.
As a result of the short half-life, 1.8 ± 0.4 hours, only a minimal increase in plasma concentrations occurred after multiple dosing. 
Zaradi kratkega razpolovnega časa (1,8  0,4 ure) je po večkratnem odmerjanju prišlo le do minimalnega porasta plazemske koncentracije.
This overall safety profile remained similar for 107 patients treated with CRIXIVAN monotherapy or in combination with NRTI(s) for up to 48 weeks. 
Ta celotni varnostni profil je ostal enak pri 107-ih bolnikih, ki so se do 48 tednov zdravili z zdravilom CRIXIVAN samim ali v kombinaciji z NRTI.
Indinavir did not alter the type, frequency, or severity of known major adverse effects associated with the use of zidovudine, didanosine, or lamivudine. 
Uporaba indinavirja ni spremenila tipa, pogostnosti ali resnosti znanih glavnih neželenih učinkov, povezanih z uporabo zidovudina, didanozina ali lamivudina.
Although the etiology is considered to be multifactorial (including corticosteroid use, alcohol consumption, severe immunosuppression, higher body mass index), cases of osteonecrosis have been reported particularly in patients with advanced HIV-disease and/or long-term exposure to combination antiretroviral therapy (CART). 
Čeprav je vzrokov verjetno več (vključno z uporabo kortikosteroidov, uživanjem alkohola, hudo imunosupresijo, višjim indeksom telesne mase), so o primerih osteonekroze poročali zlasti pri bolnikih z napredovalo boleznijo HIV in/ali dolgotrajno izpostavljenostjo kombiniranemu protiretrovirusnemu zdravljenju (CART - combination antiretroviral therapy).
Combination contraindicated due to an increased risk of myopathy including rhabdomyolysis. 
Kombinacija je kontraindicirana zaradi povečanega tveganja za miopatijo, vključno z rabdomiolizo.
• This is because reducing or missing doses will make it more likely that HIV will become resistant to CRIXIVAN. 
• Z zmanjšanjem ali izpustitvijo odmerka se bo povečalo tveganje, da virus HIV postane odporen na zdravilo CRIXIVAN.
Following initiation of indinavir/ritonavir 800/100 BID or lopinavir/ritonavir 400/100 BID, dose reduction of cyclosporine A to 5-20 % of prior dose was needed to maintain cyclosporine A levels within therapeutic range in one study. 
Po začetku dajanja indinavirja/ritonavirja 800/100 BID ali lopinavirja/ritonavirja 400/100 BID so morali v eni študiji odmerek ciklosporina A zmanjšati za 5-20 %, da se je raven ciklosporina A vzdrževala v terapevtskem razponu.
What you need to know before you take CRIXIVAN 
Kaj morate vedeti, preden boste vzeli zdravilo CRIXIVAN
Complete cross resistance was noted between indinavir and ritonavir; however, cross resistance to saquinavir varied among isolates. 
Popolno navzkrižno rezistenco so ugotovili med indinavirjem in ritonavirjem; stopnja navzkrižne rezistence s sakvinavirom pa se je med izolati spreminjala.
Indinavir should be used cautiously with other medicinal products that are potent inducers of CYP3A4. 
Indinavir je treba uporabljati previdno skupaj z drugimi zdravili, ki so močni induktorji CYP3A4.
There are no clinically significant differences in the pharmacokinetics of indinavir in HIV seropositive women compared to HIV seropositive men. 
V farmakokinetiki indinavirja pri HIV seropozitivnih ženskah in HIV seropozitivnih moških ni nobenih klinično pomembnih razlik.
• allergic reactions - signs include itchy skin, redness of the skin, ‘wheals' or ‘hives', swelling of the face, lips, tongue or throat and difficulty breathing. 
• alergijske reakcije - med znaki so srbeča koža, pordela koža, mehurji ali koprivnica, otekanje obraza, ustnic, jezika ali žrela ter težko dihanje.
If you have been told by your doctor that you cannot tolerate or digest some sugars, talk to your doctor before taking this medicine. 
Če vam je zdravnik povedal, da ne prenašate nekaterih sladkorjev, se pred jemanjem zdravila posvetujte z zdravnikom.
In dogs, a slight increase in resorptions was seen; however, all foetuses in medication-treated animals were viable, and the incidence of live foetuses in medication-treated animals was comparable to that in controls. 
Pri psih so opazili rahlo povečanje resorpcije, vendar so bili vsi plodi zdravljenih živali sposobni za življenje in je bila pojavnost živih plodov zdravljenih živali primerljiva s tisto v kontrolni skupini.
In controlled clinical trials conducted world-wide, indinavir was administered alone or in combination with other antiretroviral agents (zidovudine, didanosine, stavudine, and/or lamivudine) to approximately 2,000 patients, the majority of whom were adult Caucasian males (15 % females). 
V kontroliranih kliničnih raziskavah po vsem svetu so uporabljali indinavir sam ali v kombinaciji z drugimi protiretrovirusnimi zdravili (zidovudinom, didanozinom, stavudinom in/ali lamivudinom) pri približno 2.000 bolnikih, med katerimi je bila večina moških belcev (15 % žensk).
Phenytoin may decrease serum levels of ritonavir. 
Fenitoin lahko zniža ravni ritonavirja v serumu.
HMG-CoA REDUCTASE INHIBITORS Lovastatin, simvastatin 
ZAVIRALCI REDUKTAZE HMG CoA Lovastatin, simvastatin
CRIXIVAN is used to treat Human Immunodeficiency Virus (HIV) in adults. 
Zdravilo Crixivan se uporablja za zdravljenje okužbe s humanim imunodeficitnim virusom (HIV) pri odraslih.
Another published study evaluated the efficacy and safety of indinavir/ritonavir 400/100 mg every 12 hours in 40 antiretroviral-naïve patients. 
Druga objavljena študija je ocenila učinkovitost in varnost indinavirja/ritonavirja 400/100 mg na vsakih 12 ur pri 40-ih bolnikih, ki še niso prejemali protiretrovirusnih zdravil.
Patients with severe hepatic impairment have not been studied; therefore, no dosing recommendations can be made (see section 4.4). 
Študij pri bolnikih s hudo jetrno okvaro niso opravili, zato zanje posebnega odmerjanja ne moremo priporočiti (glejte poglavje 4.4).
If persistent severe leucocyturia is found, further investigation might be warranted. 
V primeru odkritja persistentne resne levkociturije morajo biti zagotovljene nadaljnje preiskave.
Relevant examples are cytomegalovirus retinitis, generalised and/or focal mycobacterial infections, and Pneumocystis carinii pneumonia. 
Ustrezni primeri so citomegalovirusni renitis, generalizirane in/ali žariščne okužbe z mikobakterijami in s Pneumocystis carinii povzročena pljučnica.
Co-administration may result in decreased plasma concentrations of indinavir and as a consequence an increased risk for suboptimal treatment and facilitation of development of resistance (see section 4.5). 
Pri sočasnem jemanju lahko pride do zmanjšanja plazemskih koncentracij indinavirja in posledično do zvečanja tveganja za suboptimalno zdravljenje in lažjega razvoja rezistence (glejte poglavje 4.5).
It belongs to a group of medicines called ‘protease inhibitors'. 
Spada v razred zdravil, imenovanih 'zaviralci proteaz'.
The pharmacokinetics of indinavir (400 mg) with ritonavir (100 mg) dosed twice daily was examined in two studies. 
Farmakokinetiko indinavirja (400 mg) v kombinaciji z ritonavirjem (100 mg) dvakrat na dan so preučevali v dveh študijah.
• ingrown toenails with or without infection 
• vraščeni nohti na prstih nog z okužbo ali brez
In Rhesus monkeys, administration of indinavir to neonates caused a mild exacerbation of the transient physiologic hyperbilirubinaemia seen in this species after birth. 
Pri opicah Rhesus je uporaba indinavirja pri mladičih povzročila blago poslabšanje prehodne fiziološke hiperbilirubinemije, opazne pri tej živalski vrsti po porodu.
Analysis of plasma and urine samples from subjects who received indinavir indicated that indinavir metabolites had little proteinase inhibitory activity. 
Analize vzorcev plazme in urina oseb, ki so prejemale indinavir, so pokazale, da imajo presnovki indinavirja malenkosten inhibitorni učinek na proteinazo.
In some cases, nephrolithiasis has been associated with renal insufficiency or acute renal failure; in the majority of these cases renal insufficiency and acute renal failure were reversible. 
V nekaterih primerih so bili ledvični kamni povezani z ledvično okvaro ali akutno ledvično odpovedjo; v večini teh primerov sta bili ledvična okvara in akutna ledvična odpoved reverzibilni.
The cumulative frequency of nephrolithiasis events increases with increasing exposure to CRIXIVAN; however, the risk over time remains relatively constant. 
Skupna pogostnost pojavljanja ledvičnih kamnov se poveča s povečano uporabo zdravila CRIXIVAN, vendar s časom postane tveganje relativno stalno.
Acute haemolytic anaemia 
Akutna hemolitična anemija
• morphine, fentanyl - used for pain 
• morfin, fentanil - za bolečine
If rifabutin treatment is required, alternative agents for treating HIV infection should be sought. 
Če je potrebno zdravljenje z rifabutinom, je treba izbrati alternativna zdravila za zdravljenje okužbe s HIV.
The pharmacokinetics of indinavir taken as indinavir sulphate salt (from opened hard capsules) mixed in apple sauce were generally comparable to the pharmacokinetics of indinavir taken as hard capsules, under fasting conditions. 
Farmakokinetika indinavirja, vzetega v obliki indinavirjevega sulfata (iz odprte trde kapsule), zmešanega z jabolčnim sokom, je bila na splošno primerljiva s farmakokinetiko indinavirja vzetega v obliki trdih kapsul na tešče.
No external or visceral changes were observed in rats, however, increases in the incidence of supernumerary ribs and of cervical ribs were seen. 
Pri podganah niso opazili nobenih zunanjih ali visceralnih sprememb, čeprav so opazili povečanje pojavnosti nadštevilnih reber in vratnih reber.
Concomitant use of medicinal products that are inducers of CYP3A4, such as carbamazepine, phenobarbital and phenytoin may reduce indinavir plasma concentrations. 
Sočasna uporaba zdravil, ki zavirajo CYP3A4, kot so karbamazepin, fenobarbital in fenitoin, lahko zmanjša koncentracijo indinavirja v plazmi.
• If you cannot take it without food then take CRIXIVAN with a low-fat light meal. 
• Če zdravila CRIXIVAN ne morete vzeti brez hrane, potem ga vzemite z lahkim obrokom, ki ne vsebuje veliko maščob.
Crystals have been seen in the urine of rats, one monkey, and one dog. 
V urinu podgan, ene opice in enega psa so našli kristale.
When CRIXIVAN is used with ritonavir, consult the Summary of Product Characteristics of ritonavir for additional contraindications. 
Kadar se zdravilo CRIXIVAN uporablja skupaj z ritonavirjem, glejte Povzetek glavnih značilnosti ritonavirja za dodatne kontraindikacije.
The bioavailability of a single 800-mg dose of indinavir was approximately 65 % (90 % CI, 58 - 72 %). 
Biološka uporabnost enkratnega 800 mg odmerka indinavirja je bila približno 65 % (90 % CI - "confidential interval", 58-72 %).
3 years for HDPE bottles containing 90 and 180 hard capsules. 
3 leta za HDPE plastenke z 90 in 180 trdimi kapsulami.
Adequate hydration is recommended in all patients on indinavir (see sections 4.2 and 4.8). 
Pri vseh bolnikih, ki se zdravijo z indinavirjem, priporočamo zadostno oskrbo s tekočino (glejte poglavji 4.2 in 4.8).
In zidovudine experienced patients, indinavir, zidovudine and lamivudine in combination compared with lamivudine added to zidovudine reduced the probability of AIDS defining illness or death (ADID) at 48 weeks from 13 % to 7 %. 
Pri bolnikih, zdravljenih z zidovudinom, je kombinacija indinavirja, zidovudina in lamivudina v primerjavi z lamivudinom dodanim zidovudinu zmanjšala verjetnost določitve bolezni AIDS ali smrti (ADID) po 48 tednih s 13 % na 7 %.
Similarly, in antiretroviral naive patients, indinavir with and without zidovudine compared with zidovudine alone reduced the probability of ADID at 48 weeks from 15 % with zidovudine alone to approximately 6 % with indinavir alone or in combination with zidovudine. 
Podobno je pri bolnikih, ki se še niso zdravili s protiretrovirusnimi zdravili, indinavir z ali brez zidovudina v primerjavi s samim zidovudinom zmanjšal verjetnost ADID po 48 tednih s 15 % pri zidovudinu samem na približno 6 % pri indinavirju samem ali v kombinaciji z zidovudinom.
• venlafaxine, trazodone - used for depression 
• venlafaksin, trazodon - za depresijo
Administration of indinavir to pregnant Rhesus monkeys during the third trimester did not cause a similar exacerbation in neonates; however, only limited placental transfer of indinavir occurred. 
Uporaba indinavirja v obdobju tretjega trimesečja brejosti pri mladičih opic Rhesus ni povzročila podobnega poslabšanja; prišlo je le do omejenega prehoda indinavirja preko posteljice.
Nephrolithiasis has occurred with indinavir therapy in adult patients with a cumulative frequency of 12.4 % (range across individual trials: 4.7 % to 34.4 %). 
Pri uporabi indinavirja so se pri odraslih bolnikih pojavili ledvični kamni s skupno pogostnostjo pojavljanja 12,4 % (razpon med posameznimi študijami: 4,7 % do 34,4 %).
• liver problems - people with ‘chronic hepatitis B or C' or ‘cirrhosis' who are treated with ‘antiretroviral' medicines are more likely to have serious and potentially fatal liver side effects with this medicine. 
• težave z jetri - ljudje s 'kroničnim hepatitisom B ali C' ali 'cirozo', ki se zdravijo z 'protiretrovirusnimi' zdravili, so bolj dovzetni za resne in potencialno smrtne neželene učinke na jetra.
Indinavir binds reversibly to the protease active site and inhibits competitively the enzyme, thereby preventing cleavage of the viral precursor polyproteins that occurs during maturation of the newly formed viral particle. 
Indinavir se reverzibilno veže na aktivno mesto proteaze, kompetitivno zavira encim ter tako preprečuje cepitev virusnih prekurzorskih poliproteinov, do katere pride med zorenjem novega virusnega delca.
The safety and efficacy of indinavir has not been established in patients with significant underlying liver disorders. 
Varnost in učinkovitost indinavirja pri bolnikih s pomembnimi, že obstoječimi motnjami v delovanju jeter ni bila dokazana.
• amlodipine, felodipine, nifedipine, nicardipine, digoxin, diltiazem - used for high blood pressure and some heart problems. 
• amlodipin, felodipin, nifedipin, nikardipin, digoksin, diltiazem - za zvišan krvni tlak in določene okvare srca
CRIXIVAN should be administered by physicians who are experienced in the treatment of HIV infection. 
Zdravilo CRIXIVAN mora predpisati zdravnik, ki ima izkušnje z zdravljenjem okužbe s HIV.
3; and the mean increase in percent CD4 cell counts was 1.2 %. 
3 ter povprečno povečanje odstotka števila CD4 celic 1,2 %.